Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients

Initial analysis of the synergy of programmed cell death-1 (PD-1) inhibitor and concurrent chemoradiotherapy treatment for recurrent/metastatic head and neck squamous cell carcinoma patients

Abstract Background Programmed cell death-1 (PD-1) inhibitor was proven to be useful for the recurrent/metastatic head and neck squamous carcinoma (R/M HNSCC) patients. Though both PD-1 inhibitor alone and combination with chemotherapy showed some benefit for PFS and OS, the survival outcome was sti...

Full description

Bibliographic Details
Main Authors: Lu Li, Lu Chen, Lu Yan, Yueqian Guo, Fang Li, Ming Fan, Mei Lan, Xin Lai, Jie Zhou, Yecai Huang, Peng Xu, Jinyi Lang, Mei Feng
Format: Article
Language:English
Published: BMC 2023-07-01
Series:Radiation Oncology
Subjects:
Recurrent
Metastatic
Head and neck squamous cell carcinoma
Chemoradiotherapy
PD-1 inhibitors
Online Access:https://doi.org/10.1186/s13014-023-02310-8

Internet

https://doi.org/10.1186/s13014-023-02310-8

Similar Items